Personalized medicine

Thanks to the advent at the turn of last century of the new “Omics” research approaches (genomics, proteomics, transcriptomics, metabolomics, ...) the pharmaceutical industry has entered the personalized medicine era. More and more diagnostics tests (ELISA, PCR, Next Generation Sequencing, medical imaging) has been successfully developed to individualize medical treatments ensuring the best chance of fighting off diseases such as cancers.

Progenus proposes PCR and Next Generation Sequencing (NGS) -based services to design and validate in-vitro diagnostic tests for:

  • Disease susceptibility (cancers, auto-immune diseases, central nervous system degenerative diseases, ...)
  • Disease prediction
  • Disease detection (viral, bacterial, fungal, ... infections)